Methods and compositions for oral administration of proteins

ABSTRACT

This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority of U.S. Provisional Ser. No.60/713,716, filed on Sep. 6, 2005, which is included in its entirety byreference herein.

FIELD OF INVENTION

This invention provides compositions comprising a protein and an omega-3fatty acid, and a method for administering same.

BACKGROUND OF THE INVENTION

Due to improved biotechnology, the accessibility of biologically activepeptides to the pharmaceutical industry has increased considerably.However, a limiting factor in the development of peptide drugs is therelative ineffectiveness when given perorally. Almost all peptide drugsare parenterally administered, although parenterally administeredpeptide drugs are often connected with low patient compliance.

Insulin is a medicament used to treat patients suffering from diabetes,and is the only treatment for insulin-dependent diabetes mellitus.Diabetes Mellitus is characterized by a pathological condition ofabsolute or relative insulin deficiency, leading to hyperglycemia, andis one of the main threats to human health in the 21st century. Theglobal figure of people with diabetes is set to rise to 220 million in2010, and 300 million in 2025. Type I diabetes is caused primarily bythe failure of the pancreas to produce insulin. Type II diabetes,involves a lack of responsiveness of the body to the action of insulin.

Approximately 20%-30% of all diabetics use daily insulin injections tomaintain their glucose levels. An estimated 10% of all diabetics aretotally dependent on insulin injections.

Currently, the only route of insulin administration is injection. Dailyinjection of insulin is causes considerable suffering for patients. Sideeffects such as lipodystrophy at the site of the injection, lipatrophy,lilpohypertrophy, and occasional hypoglycemia are known to occur. Inaddition, subcutaneous administration of insulin does not typicallyprovide the fine continuous regulation of metabolism that occursnormally with insulin secreted from the pancreas directly into the livervia the portal vein.

The present invention addresses the need for an alternate solution foradministration of insulin.

SUMMARY OF THE INVENTION

This invention provides compositions comprising a protein and an omega-3fatty acid, method for treating diabetes mellitus, comprisingadministering same, and methods for oral administration of a proteinwith an enzymatic activity, comprising orally administering same.

In one embodiment, the present invention provides a compositioncomprising an insulin protein and an omega-3 fatty acid.

In another embodiment, the present invention provides a method for oraladministration of a protein with an enzymatic activity to a subject,whereby a substantial fraction of the protein retains the enzymaticactivity after absorption through an intestinal mucosal barrier of thesubject, comprising administering orally to the subject a pharmaceuticalcomposition comprising the protein and an omega-3 fatty acid, therebyorally administering a protein with an enzymatic activity to a subject.

In another embodiment, the present invention provides a method fortreating diabetes mellitus in a subject, comprising administering orallyto the subject a pharmaceutical composition comprising insulin and anomega-3 fatty acid, thereby treating diabetes mellitus.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides compositions and methods comprising a proteinand an omega-3 fatty acid. In one embodiment, the protein having amolecular weight up to 200,000 Daltons. In a preferred embodiment, theprotein having a molecular weight up to 100,000 Daltons. In oneembodiment, the present invention further provides an enhancer whichenhances absorption through the intestines.

In one embodiment, the protein is an enzyme. In some embodiments, theprotein is a receptor ligand, transporter, or a storage protein. In oneembodiment, the protein is a structural protein.

In some embodiments, the enzyme is an oxidoreductase, transferase,hydrolase, lyase, isomerase, or ligase. In some embodiments,oxidoreductases act on the aldehyde or oxo group of donors, on the CH—CHgroup of donors, on the CH—NH(2) group of donors, on the CH—NH group ofdonors, on NADH or NADPH, on the CH—OH group of donors, on nitrogenouscompounds as donors, on a sulfur group of donors, on a heme group ofdonors, on diphenols and related substances as donors, on a peroxide asacceptor, on hydrogen as donor, on single donors with incorporation ofmolecular oxygen, on paired donors, on superoxide as acceptor, oxidizingmetal ions, on CH or CH(2) groups, on iron-sulfur proteins as donors, onreduced flavodoxin as donor, on phosphorus or arsenic in donors, or onx-H and y-H to form an x-y bond.

In some embodiments, transferases are acyltransferases orglycosyltransferases. In some embodiments, transferases transferaldehyde or ketone residues. In some embodiments, transferases transferalkyl or aryl groups, other than methyl groups. In some embodiments,transferases transfer nitrogenous, phosphorous, sulfur or seleniumcontaining groups.

In some embodiments, hydrolases are glycosylases or act on ether bonds,on peptide bonds, on carbon-nitrogen bonds, other than peptide bonds, onacid anhydrides, on carbon-carbon bonds, on halide bonds, onphosphorus-nitrogen bonds, on sulfur-nitrogen bonds, oncarbon-phosphorus bonds, on sulfur-sulfur bonds, or on carbon-sulfurbonds.

In some embodiments, lyases are carbon-carbon lyases, carbon-oxygenlyases, carbon-nitrogen lyases, carbon-sulfur lyases, carbon-halidelyases, phosphorus-oxygen lyases, or other lyases.

In some embodiments, isomerases are racemases or epimerases,cis-trans-isomerases, intramolecular oxidoreductases, intramoleculartransferases, intramolecular lyases, or other isomerases.

In some embodiments, ligases form carbon-sulfur bonds, carbon-nitrogenbonds, carbon-carbon bonds, phosphoric ester bonds, or nitrogen-metalbonds.

In some embodiments, transporter proteins are annexins, ATP-bindingcassette transporters, hemoglobin, ATPases, calcium channels, potassiumchannels, sodium channels, or solute carriers.

In some embodiments, storage proteins comprise albumins, lactoglobulins,casein ovomucin, ferritin, phosvitin, lactoferrin, or vitellogenin. Inone embodiment, albumins comprise avidin, ovalbumin, serum albumin,parvalbumin, c-reactive protein prealbumin, conalbumin, ricin,lactalbumin, methemalbumin, or transthyretin.

In some embodiments, structural proteins comprise amyloid, collagenelastin, or fibrillin.

In some embodiments, the protein is a viral protein, bacterial protein,invertebrate protein, or vertebrate protein. In some embodiments, theprotein is a recombinant protein. In one embodiment, the protein is arecombinant protein. In one embodiment, the recombinant protein is arecombinant human protein.

In one embodiment, the present invention provides a compositioncomprising an insulin protein and an omega-3 fatty acid. As providedherein (Examples), such compositions have utility in the oraladministration of insulin, whereby the insulin is absorbed by theintestines into the bloodstream in an active form.

In another embodiment, the present invention provides a compositioncomprising a protein with enzymatic activity and an omega-3 fatty acid.

In one embodiment, the insulin of methods and compositions of thepresent invention is human insulin. In another embodiment, the insulinis a recombinant insulin. In another embodiment, the insulin isrecombinant human insulin. In another embodiment, the insulin is bovineinsulin. In another embodiment, the insulin is porcine insulin. Inanother embodiment, the insulin is whale insulin. In another embodiment,the insulin is a metal complex of insulin (e.g. a zinc complex ofinsulin, protamine zinc insulin, or globin zinc).

In another embodiment, the insulin is regular insulin. In anotherembodiment, the insulin is fast-acting insulin. In another embodiment,the insulin is lente insulin. In another embodiment, the insulin issemilente insulin. In another embodiment, the insulin is Ultralenteinsulin. In another embodiment, the insulin is NPH insulin. In anotherembodiment, the insulin is glargine insulin. In another embodiment, theinsulin is lispro insulin. In another embodiment, the insulin is aspartinsulin. In another embodiment, the insulin is a combination of two ormore of any of the above types of insulin. In another embodiment, theinsulin is any other type of insulin known in the art. Each possibilityrepresents a separate embodiment of the present invention.

In one embodiment, the amount of insulin utilized in methods andcompositions of the present invention is 0.5-3 units (u)/kg in humans.In one embodiment, the units used to measure insulin in methods andcompositions of the present invention are USP Insulin Units. In oneembodiment, the units used to measure insulin are milligrams. In anotherembodiment, one USP Insulin Unit is equivalent to 45.5 mg insulin.

In another embodiment, the amount of insulin is 0.1-1 u/kg. In anotherembodiment, the amount is 0.2-1 u/kg. In another embodiment, the amountis 0.3-1 u/kg. In another embodiment, the amount is 0.5-1 u/kg. Inanother embodiment, the amount is 0.1-2 u/kg. In another embodiment, theamount is 0.2-2 u/kg.

In another embodiment, the amount is 0.3-2 u/kg. In another embodiment,the amount is 0.5-2 u/kg. In another embodiment, the amount is 0.7-2u/kg. In another embodiment, the amount is 1-2 u/kg. In anotherembodiment, the amount is 1.2-2 u/kg. In another embodiment, the amountis 1-1.2 u/kg. In another embodiment, the amount is 1-1.5 u/kg. Inanother embodiment, the amount is 1-2.5 u/kg. In another embodiment, theamount is 1-3 u/kg. In another embodiment, the amount is 2-3 u/kg. Inanother embodiment, the amount is 1-5 u/kg. In another embodiment, theamount is 2-5 u/kg. In another embodiment, the amount is 3-5 u/kg.

In another embodiment, the amount of insulin is 0.1 u/kg. In anotherembodiment, the amount is 0.2 u/kg. In another embodiment, the amount is0.3 u/kg. In another embodiment, the amount is 0.4 u/kg. In anotherembodiment, the amount is 0.5 u/kg. In another embodiment, the amount is0.6 u/kg. In another embodiment, the amount is 0.8 u/kg. In anotherembodiment, the amount is 1 u/kg. In another embodiment, the amount is1.2 u/kg. In another embodiment, the amount is 1.4 u/kg. In anotherembodiment, the amount is 1.6 u/kg. In another embodiment, the amount is1.8 u/kg. In another embodiment, the amount is 2 u/kg. In anotherembodiment, the amount is 2.2 u/kg. In another embodiment, the amount is2.5 u/kg. In another embodiment, the amount is 3 u/kg.

In another embodiment, the amount of insulin is 1-10 u. In anotherembodiment, the amount is 2-10 u. In another embodiment, the amount is3-10 u. In another embodiment, the amount is 5-10 u. In anotherembodiment, the amount is 1-20 u. In another embodiment, the amount is2-20 u. In another embodiment, the amount is 3-20 u. In anotherembodiment, the amount is 5-20 u. In another embodiment, the amount is7-20 u. In another embodiment, the amount is 10-20 u. In anotherembodiment, the amount is 12-20 u. In another embodiment, the amount is10-12 u. In another embodiment, the amount is 10-15 u. In anotherembodiment, the amount is 10-25 u. In another embodiment, the amount is10-30 u. In another embodiment, the amount is 20-30 u. In anotherembodiment, the amount is 10-50 u. In another embodiment, the amount is20-50 u. In another embodiment, the amount is 30-50 u. In anotherembodiment, the amount is 20-100 u. In another embodiment, the amount is30-100 u. In another embodiment, the amount is 100-150 u. In anotherembodiment, the amount is 100-250 u. In another embodiment, the amountis 100-300 u. In another embodiment, the amount is 200-300 u. In anotherembodiment, the amount is 100-500 u. In another embodiment, the amountis 200-500 u. In another embodiment, the amount is 300-500 u. In anotherembodiment, the amount is 200-1000 u. In another embodiment, the amountis 300-1000 u.

In another embodiment, the amount of insulin is 1 u. In anotherembodiment, the amount is 2 u. In another embodiment, the amount is 3 u.In another embodiment, the amount is 4 u. In another embodiment, theamount is 5 u. In another embodiment, the amount is 6 u. In anotherembodiment, the amount is 8 u. In another embodiment, the amount is 10u. In another embodiment, the amount is 12 u. In another embodiment, theamount is 14 u. In another embodiment, the amount is 16 u. In anotherembodiment, the amount is 18 u. In another embodiment, the amount is 20u. In another embodiment, the amount is 22 u. In another embodiment, theamount is 25 u. In another embodiment, the amount is 30 u. In anotherembodiment, the amount is 50 u. In another embodiment, the amount is 80u. In another embodiment, the amount is 100 u. In another embodiment,the amount is 120 u. In another embodiment, the amount is 140 u. Inanother embodiment, the amount is 160 u. In another embodiment, theamount is 180 u. In another embodiment, the amount is 200 u. In anotherembodiment, the amount is 300 u. In another embodiment, the amount is500 u.

In another embodiment, the use of sustained release dosage forms (e.g.sustained release microencapsulation) enables the treatment frequency tobe reduced to once or twice a day. In another embodiment, the insulindosage is increased correspondingly with decreasing frequency ofadministration.

Each amount of insulin represents a separate embodiment of the presentinvention.

Methods of measuring insulin levels are well known in the art. In oneembodiment, levels of recombinant insulin are measuring using a humaninsulin radio-immunoassay (RIA) kit, e.g. the kit manufactured by LincoResearch Inc, (St. Charles, Mo.). In another embodiment, levels of Cpeptide are measured as well, to determine the relative contributions ofendogenous and exogenous insulin to observed rises in insulin levels. Inanother embodiment, insulin ELISA kits are used. In another embodiment,insulin levels are measured by any other method known in the art. Eachpossibility represents a separate embodiment of the present invention.

In some embodiments, omega-3 fatty acid can be found in vegetablesources such as the seeds of chia, perilla, flax, walnuts, purslane,lingonberry, seabuckthorn, and hemp. In some embodiments, omega-3 fattyacids can also be found in the fruit of the acai palm. In anotherembodiment, the omega-3 fatty acid has been provided in the form of asynthetic omega-3 fatty acid. In one embodiment, the omega-3 fatty acidof methods and compositions of the present invention has been providedto the composition in the form of a fish oil. In another embodiment, theomega-3 fatty acid has been provided in the form of canola oil. Inanother embodiment, the omega-3 fatty acid has been provided in the formof flaxseed oil. In another embodiment, the omega-3 fatty acid has beenprovided in the form of any other omega-3 fatty acid-rich source knownin the art. In another embodiment, the omega-3 fatty acid has beenprovided in the form of a synthetic omega-3 fatty acid. Each form ofomega-3 fatty acids represents a separate embodiment of the presentinvention.

In another embodiment, the omega-3 fatty acid of methods andcompositions of the present invention is an omega-3 polyunsaturatedfatty acid. In another embodiment, the omega-3 fatty acid is DHA, anomega-3, polyunsaturated, 22-carbon fatty acid also referred to as 4, 7,10, 13, 16, 19-docosahexaenoic acid. In another embodiment, the omega-3fatty acid is a-linolenic acid (9, 12, 15-octadecatrienoic acid). Inanother embodiment, the omega-3 fatty acid is stearidonic acid (6, 9,12, 15-octadecatetraenoic acid). In another embodiment, the omega-3fatty acid is eicosatrienoic acid (ETA; 11, 14, 17-eicosatrienoic acid).In another embodiment, the omega-3 fatty acid is eicsoatetraenoic acid(8, 11, 14, 17-eicosatetraenoic acid). In one embodiment, the omega-3fatty acid is eicosapentaenoic acid (EPA; 5, 8, 11, 14,17-eicosapentaenoic acid). In another embodiment, the omega-3 fatty acidis eicosahexaenoic acid (also referred to as “EPA”; 5, 7, 9, 11, 14,17-eicosahexaenoic acid). In another embodiment, the omega-3 fatty acidis docosapentaenoic acid (DPA; 7, 10, 13, 16, 19-docosapenatenoic acid).In another embodiment, the omega-3 fatty acid is tetracosahexaenoic acid(6, 9, 12, 15, 18, 21-tetracosahexaenoic acid). In another embodiment,the omega-3 fatty acid is any other omega-3 fatty acid known in the art.Each omega-3 fatty acid represents a separate embodiment of the presentinvention.

In another embodiment, compositions of the present invention furthercomprise an inhibitor of a protease. As provided herein, proteaseinhibitors enhance the ability of omega-3 fatty acids to protect insulinand facilitate its absorption in the intestine.

In some embodiments, protease inhibitor inhibits the function ofpeptidases. In one embodiment, protease inhibitors enhance the abilityof omega-3 fatty acids to protect the protein of the present inventionand facilitate its absorption in the intestine. In some embodiments, theprotease inhibitor of the present invention is a protein. In someembodiments, protease inhibitors comprise cysteine protease inhibitors,serine protease inhibitors (serpins), trypsin inhibitors, threonineprotease inhibitors, aspartic protease inhibitors, metallo proteaseinhibitors. In some embodiments, protease inhibitors comprise suicideinhibitor, transition state inhibitor, or chelating agents.

In one embodiment, the protease inhibitor is soybean trypsin inhibitor(SBTI). In another embodiment, the protease inhibitor is AEBSF-HCL. Inanother embodiment, the inhibitor is (epsilon)-aminocaproic acid. Inanother embodiment, the inhibitor is (alpha) 1-antichymotypsin. Inanother embodiment, the inhibitor is antipain. In another embodiment,the inhibitor is antithrombin III. In another embodiment, the inhibitoris (alpha) 1-antitrypsin ([alpha] 1-proteinase inhibitor). In anotherembodiment, the inhibitor is APMSF-HCI (4-amidinophenyl-methanesulfonyl-fluoride). In another embodiment, the inhibitor is sprotinin.In another embodiment, the inhibitor is benzamidine-HCI. In anotherembodiment, the inhibitor is chymostatin. In another embodiment, theinhibitor is DFP (diisopropylfluoro-phosphate). In another embodiment,the inhibitor is leupeptin. In another embodiment, the inhibitor isPEFABLOC® SC (4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride).In another embodiment, the inhibitor is PMSF (phenylmethyl sulfonylfluoride). In another embodiment, the inhibitor is TLCK(1-Chloro-3-tosylamido-7-amino-2-heptanone HO). In another embodiment,the inhibitor is TPCK (1-Chloro-3-tosylamido-4-phenyl-2-butanone). Inanother embodiment, the inhibitor is trypsin inhibitor from egg white(Ovomucoid). In another embodiment, the inhibitor is trypsin inhibitorfrom soybean. In another embodiment, the inhibitor is aprotinin. Inanother embodiment, the inhibitor is pentamidine isethionate. In anotherembodiment, the inhibitor is pepstatin. In another embodiment, theinhibitor is guanidium. In another embodiment, the inhibitor isalpha2-macroglobulin. In another embodiment, the inhibitor is achelating agent of zinc. In another embodiment, the inhibitor isiodoacetate. In another embodiment, the inhibitor is zinc. Eachpossibility represents a separate embodiment of the present invention.

In another embodiment, the amount of protease inhibitor utilized inmethods and compositions of the present invention is 0.1 mg/dosage unit.In another embodiment, the amount of protease inhibitor is 0.2 mg/dosageunit. In another embodiment, the amount is 0.3 mg/dosage unit. Inanother embodiment, the amount is 0.4 mg/dosage unit. In anotherembodiment, the amount is 0.6 mg/dosage unit. In another embodiment, theamount is 0.8 mg/dosage unit. In another embodiment, the amount is 1mg/dosage unit. In another embodiment, the amount is 1.5 mg/dosage unit.In another embodiment, the amount is 2 mg/dosage unit. In anotherembodiment, the amount is 2.5 mg/dosage unit. In another embodiment, theamount is 3 mg/dosage unit. In another embodiment, the amount is 5mg/dosage unit. In another embodiment, the amount is 7 mg/dosage unit.In another embodiment, the amount is 10 mg/dosage unit. In anotherembodiment, the amount is 12 mg/dosage unit. In another embodiment, theamount is 15 mg/dosage unit. In another embodiment, the amount is 20mg/dosage unit. In another embodiment, the amount is 30 mg/dosage unit.In another embodiment, the amount is 50 mg/dosage unit. In anotherembodiment, the amount is 70 mg/dosage unit. In another embodiment, theamount is 100 mg/dosage unit.

In another embodiment, the amount of protease inhibitor is 0.1-1mg/dosage unit. In another embodiment, the amount of protease inhibitoris 0.2-1 mg/dosage unit. In another embodiment, the amount is 0.3-1mg/dosage unit. In another embodiment, the amount is 0.5-1 mg/dosageunit. In another embodiment, the amount is 0.1-2 mg/dosage unit. Inanother embodiment, the amount is 0.2-2 mg/dosage unit. In anotherembodiment, the amount is 0.3-2 mg/dosage unit. In another embodiment,the amount is 0.5-2 mg/dosage unit. In another embodiment, the amount is1-2 mg/dosage unit. In another embodiment, the amount is 1-10 mg/dosageunit. In another embodiment, the amount is 2-10 mg/dosage unit. Inanother embodiment, the amount is 3-10 mg/dosage unit. In anotherembodiment, the amount is 5-10 mg/dosage unit. In another embodiment,the amount is 1-20 mg/dosage unit. In another embodiment, the amount is2-20 mg/dosage unit. In another embodiment, the amount is 3-20 mg/dosageunit. In another embodiment, the amount is 5-20 mg/dosage unit. Inanother embodiment, the amount is 10-20 mg/dosage unit. In anotherembodiment, the amount is 10-100 mg/dosage unit. In another embodiment,the amount is 20-100 mg/dosage unit. In another embodiment, the amountis 30-100 mg/dosage unit. In another embodiment, the amount is 50-100mg/dosage unit. In another embodiment, the amount is 10-200 mg/dosageunit. In another embodiment, the amount is 20-200 mg/dosage unit. Inanother embodiment, the amount is 30-200 mg/dosage unit. In anotherembodiment, the amount is 50-200 mg/dosage unit. In another embodiment,the amount is 100-200 mg/dosage unit.

In another embodiment, the amount of protease inhibitor utilized inmethods and compositions of the present invention is 1000 k.i.u.(kallikrein inactivator units)/pill. In another embodiment, the amountis 10 k.i.u./dosage unit. In another embodiment, the amount is 12k.i.u./dosage unit. In another embodiment, the amount is 15k.i.u./dosage unit. In another embodiment, the amount is 20k.i.u./dosage unit. In another embodiment, the amount is 30k.i.u./dosage unit. In another embodiment, the amount is 40k.i.u./dosage unit. In another embodiment, the amount is 50k.i.u./dosage unit. In another embodiment, the amount is 70k.i.u./dosage unit. In another embodiment, the amount is 100k.i.u./dosage unit. In another embodiment, the amount is 150k.i.u./dosage unit. In another embodiment, the amount is 200k.i.u./dosage unit. In another embodiment, the amount is 300k.i.u./dosage unit. In another embodiment, the amount is 500k.i.u./dosage unit. In another embodiment, the amount is 700k.i.u./dosage unit. In another embodiment, the amount is 1500k.i.u./dosage unit. In another embodiment, the amount is 3000k.i.u./dosage unit. In another embodiment, the amount is 4000k.i.u./dosage unit. In another embodiment, the amount is 5000k.i.u./dosage unit.

Each amount of protease inhibitor represents a separate embodiment ofthe present invention.

In another embodiment, the protease targeted by the protease inhibitorof methods and compositions of the present invention is a serineprotease. In another embodiment, the protease is trypsin. In anotherembodiment, the protease is chymotrypsin. In another embodiment, theprotease is carboxypeptidase. In another embodiment, the protease isaminopeptidase. In another embodiment, the protease is any otherprotease that functions in the duodenum or the small intestine. Eachpossibility represents a separate embodiment of the present invention.

In another embodiment, compositions of the present invention furthercomprise a substance that enhances absorption of the insulin through anintestinal mucosal barrier. Such a substance is referred to herein as an“enhancer.” As provided herein, enhancers, when used together withomega-3 fatty acids, enhance the ability of insulin to be absorbed inthe intestine.

In one embodiment, the enhancer is didecanoylphosphatidylcholine (DDPC).In one embodiment, the enhancer is a chelating agent such asethylenediaminetetraacetic acid (EDTA) or egtazic acid EGTA. In apreferred embodiment, EDTA is sodium-EDTA. In some embodiments, theenhancer is NO donor. In some embodiments, the enhancer is a bile acid,glycine-conjugated form of a bile acid, or an alkali metal salt. In oneembodiment, absorption enhancement is achieved through utilization of acombination of α-galactosidase and β-mannanase. In some embodiments, theenhancer is a fatty acid such as sodium caprate. In one embodiment, theenhancer is sodium glycocholate. In one embodiment, the enhancer issodium salicylate. In one embodiment, the enhancer isn-dodecyl-β-D-maltopyranoside.

In some embodiments, surfactants serve as absorption enhancer. In oneembodiment, the enhancer is chitisan such as N,N,N-trimethyl chitosanchloride (TMC).

In one embodiment, NO donors of the present invention comprise3-(2-Hydroxy-1-(1-methylethyl)-2-nitrosohydrazino)-1-propanamine,N-ethyl-2-(1-ethyl-hydroxy-2-nitrosohydrazino)-ethanamine, orS-Nitroso-N-acetylpenicillamine

In another embodiment, the bile acid is cholic acid. In anotherembodiment, the bile acid is chenodeoxycholic acid. In anotherembodiment, the bile acid is taurocholic acid. In another embodiment,the bile acid is taurochenodeoxycholic acid. In another embodiment, thebile acid is glycocholic acid. In another embodiment, the bile acid isglycochenocholic acid. In another embodiment, the bile acid is 3beta-monohydroxychloric acid. In another embodiment, the bile acid islithocholic acid. In another embodiment, the bile acid is 5beta-cholanic acid. In another embodiment, the bile acid is3,12-diol-7-one-5 beta-cholanic acid. In another embodiment, the bileacid is 3 alpha-hydroxy-12-ketocholic acid. In another embodiment, thebile acid is 3 beta-hydroxy-12-ketocholic acid. In another embodiment,the bile acid is 12 alpha-3 beta-dihydrocholic acid. In anotherembodiment, the bile acid is ursodesoxycholic acid.

In one embodiment, the enhancer is a nonionic surfactant. In oneembodiment, the enhancer is a nonionic polyoxyethylene ether surfaceactive agent (e.g one having an HLB value of 6 to 19, wherein theaverage number of polyoxyethylene units is 4 to 30). In anotherembodiment, the enhancer is an anionic surface active agents. In anotherembodiment, the enhancer is a cationic surface active agent. In anotherembodiment, the enhancer is an ampholytic surface active agent. In oneembodiment, zwitteruionic surfactants such as acylcarnitines serve asabsorption enhancers.

In another embodiment, the amount of enhancer utilized in methods andcompositions of the present invention is 0.1 mg/dosage unit. In anotherembodiment, the amount of enhancer is 0.2 mg/dosage unit. In anotherembodiment, the amount is 0.3 mg/dosage unit. In another embodiment, theamount is 0.4 mg/dosage unit. In another embodiment, the amount is 0.6mg/dosage unit. In another embodiment, the amount is 0.8 mg/dosage unit.In another embodiment, the amount is 1 mg/dosage unit. In anotherembodiment, the amount is 1.5 mg/dosage unit. In another embodiment, theamount is 2 mg/dosage unit. In another embodiment, the amount is 2.5mg/dosage unit. In another embodiment, the amount is 3 mg/dosage unit.In another embodiment, the amount is 5 mg/dosage unit. In anotherembodiment, the amount is 7 mg/dosage unit. In another embodiment, theamount is 10 mg/dosage unit. In another embodiment, the amount is 12mg/dosage unit. In another embodiment, the amount is 15 mg/dosage unit.In another embodiment, the amount is 20 mg/dosage unit. In anotherembodiment, the amount is 30 mg/dosage unit. In another embodiment, theamount is 50 mg/dosage unit. In another embodiment, the amount is 70mg/dosage unit. In another embodiment, the amount is 100 mg/dosage unit.

In another embodiment, the amount of enhancer is 0.1-1 mg/dosage unit.In another embodiment, the amount of enhancer is 0.2-1 mg/dosage unit.In another embodiment, the amount is 0.3-1 mg/dosage unit. In anotherembodiment, the amount is 0.5-1 mg/dosage unit. In another embodiment,the amount is 0.1-2 mg/dosage unit. In another embodiment, the amount is0.2-2 mg/dosage unit. In another embodiment, the amount is 0.3-2mg/dosage unit. In another embodiment, the amount is 0.5-2 mg/dosageunit. In another embodiment, the amount is 1-2 mg/dosage unit. Inanother embodiment, the amount is 1-10 mg/dosage unit. In anotherembodiment, the amount is 2-10 mg/dosage unit. In another embodiment,the amount is 3-10 mg/dosage unit. In another embodiment, the amount is5-10 mg/dosage unit. In another embodiment, the amount is 1-20 mg/dosageunit. In another embodiment, the amount is 2-20 mg/dosage unit. Inanother embodiment, the amount is 3-20 mg/dosage unit. In anotherembodiment, the amount is 5-20 mg/dosage unit. In another embodiment,the amount is 10-20 mg/dosage unit. In another embodiment, the amount is10-100 mg/dosage unit. In another embodiment, the amount is 20-100mg/dosage unit. In another embodiment, the amount is 30-100 mg/dosageunit. In another embodiment, the amount is 50-100 mg/dosage unit. Inanother embodiment, the amount is 10-200 mg/dosage unit. In anotherembodiment, the amount is 20-200 mg/dosage unit. In another embodiment,the amount is 30-200 mg/dosage unit. In another embodiment, the amountis 50-200 mg/dosage unit. In another embodiment, the amount is 100-200mg/dosage unit.

Each type and amount of enhancer represents a separate embodiment of thepresent invention.

In another embodiment, compositions of the present invention furthercomprise a coating that inhibits digestion of the composition in thestomach of a subject.

In one embodiment, coating inhibits digestion of the composition in thestomach of a subject. In one embodiment, the coated dosage forms of thepresent invention release drug when pH move towards alkaline range. Inone embodiment, coating is a monolayer, wherein in other embodimentscoating applied in multilayers. In one embodiment, coating is abioadhesive polymer that selectively binds the intestinal mucosa andthus enables drug release in the attachment site. In one embodiment, theenteric coating is an enteric film coating. In some embodiment, coatingcomprises biodegradable polysaccharide, chitosan, aquateric aqueous,aquacoat ECD, azo polymer, cellulose acetate phthalate, celluloseacetate trimelliate, hydroxypropylmethyl cellulose phthalate, gelatin,poly vinyl acetate phthalate, hydrogel, pulsincap, or a combinationthereof. In one embodiment, pH sensitive coating will be used accordingto the desired release site and/or profile as known to one skilled inthe art.

In one embodiment, the coating is an enteric coating. Methods forenteric coating are well known in the art, and are described, forexample, in Siepmann F, Siepmann J et al, Blends of aqueous polymerdispersions used for pellet coating: importance of the particle size. JControl Release 2005; 105(3): 226-39; and Huyghebaert N, Vermeire A,Remon J P. In vitro evaluation of coating polymers for enteric coatingand human ileal targeting. Int J Pharm 2005; 298(1): 26-37. Each methodrepresents a separate embodiment of the present invention.

In another embodiment, Eudragit®, an acrylic polymer, is used as theenteric coating. The use of acrylic polymers for the coating ofpharmaceutical preparations is well known in the art. Eudragit AcrylicPolymers have been shown to be safe, and are neither absorbed normetabolized by the body, but rather are eliminated.

In another embodiment, the coating is a gelatin coating. In anotherembodiment, microencapsulation is used to protect the insulin againstdecomposition in the stomach. Methods for applying a gelatin coating andfor microencapsulation are well known in the art. Each method representsa separate embodiment of the present invention.

In another embodiment, the coating is a film-coating. In anotherembodiment, the coating is ethylcellulose. In another embodiment, thecoating is a water-based dispersion of ethylcellulose, e.g.hydroxypropylmethylcelullose (HPMC) E15. In another embodiment, thecoating is a gastro-resistant coatings, e.g. a polymer containingcarboxylic acid groups as a functional moiety. In another embodiment,the coating is a monolithic matrix. In another embodiment, the coatingis a cellulose ether (e.g. hypromellose (HPMC). Each type of coatingrepresents a separate embodiment of the present invention.

In another embodiment, a multiparticulate dosage forms is used toinhibit digestion of the composition in the stomach.

Each type of coating, dosage form, etc, that inhibits digestion of thecomposition in the stomach represents a separate embodiment of thepresent invention.

In another embodiment, the present invention provides a method for oraladministration of a protein with an enzymatic activity to a subject,whereby a substantial fraction of the protein retains the enzymaticactivity after absorption through an intestinal mucosal barrier of thesubject, comprising administering orally to the subject a pharmaceuticalcomposition comprising the protein and an omega-3 fatty acid, therebyorally administering a protein with an enzymatic activity to a subject.

In one embodiment, the protein is a recombinant protein. In oneembodiment, the protein is an insulin. In another embodiment, theprotein is a glucagon. In another embodiment, the protein is aninterferon gamma. In another embodiment, the protein is an interferonalpha. In another embodiment, the protein is a growth hormone. Inanother embodiment, the protein is an erythropoietin. In anotherembodiment, the protein is granulocyte colony stimulating factor(G-CSF). In another embodiment, the protein is any other protein knownin the art.

In another embodiment, the protein is a growth hormone. In oneembodiment, the growth hormone is somatotropin. In another embodiment,the growth hormone is Insulin Growth Factor-I (IGF-I). In anotherembodiment, the growth hormone is any other growth hormone known in theart.

In another embodiment, the protein has a molecular weight (MW) of 1-50kilodalton (kDa). In another embodiment, the MW is 1-45 kDa. In anotherembodiment, the MW is 1-40 kDa. In another embodiment, the MW is 1-35kDa. In another embodiment, the MW is 1-30 kDa. In another embodiment,the MW is 1-25 kDa. In another embodiment, the MW is 1-20 kDa. Inanother embodiment, the MW is 10-50 kDa. In another embodiment, the MWis 15-50 kDa. In another embodiment, the MW is 20-50 kDa. In anotherembodiment, the MW is 25-50 kDa. In another embodiment, the MW is 30-50kDa. In another embodiment, the MW is 35-50 kDa. In another embodiment,the MW is 1-100 kDa. In another embodiment, the MW is 1-90 kDa. Inanother embodiment, the MW is 1-80 kDa. In another embodiment, the MW is1-70 kDa. In another embodiment, the MW is 1-60 kDa. In anotherembodiment, the MW is 10-100 kDa. In another embodiment, the MW is15-100 kDa. In another embodiment, the MW is 20-100 kDa. In anotherembodiment, the MW is 25-100 kDa. In another embodiment, the MW is30-100 kDa. In another embodiment, the MW is 10-80 kDa. In anotherembodiment, the MW is 15-80 kDa. In another embodiment, the MW is 20-80kDa. In another embodiment, the MW is 25-80 kDa. In another embodiment,the MW is 30-80 kDa. Each possibility represents a separate embodimentof the present invention.

In another embodiment, the MW is less than 20 kDa. In anotherembodiment, the MW is less than 25 kDa. In another embodiment, the MW isless than 30 kDa. In another embodiment, the MW is less than 35 kDa. Inanother embodiment, the MW is less than 40 kDa. In another embodiment,the MW is less than 45 kDa. In another embodiment, the MW is less than50 kDa. In another embodiment, the MW is less than 55 kDa. In anotherembodiment, the MW is less than 60 kDa. In another embodiment, the MW isless than 65 kDa. In another embodiment, the MW is less than 70 kDa. Inanother embodiment, the MW is less than 75 kDa. In another embodiment,the MW is less than 80 kDa. In another embodiment, the MW is less than85 kDa. In another embodiment, the MW is less than 90 kDa. In anotherembodiment, the MW is less than 95 kDa. In another embodiment, the MW isless than 100 kDa.

The molecular weights of some of the proteins mentioned above are asfollows: insulin—6 kilodalton (kDa); glucagon—3.5 kDa; interferon, 28kDa, growth hormone—21.5-47 kDa; human serum albumin—69 kDa;erythropoietin—34 kDa; G-CSF-30-34 kDa. Thus, in one embodiment, themolecular weight of these proteins is appropriate for administration bymethods of the present invention.

In another embodiment, methods and compositions of the present inventionare used to administer a human serum albumin. Human serum albumin isnot, in one embodiment, considered to be a pharmaceutically-activecomponent; however, it can be used in the context of the presentinvention as a therapeutically-beneficial carrier for an activecomponent.

Each type of protein represents a separate embodiment of the presentinvention.

In another embodiment, the present invention provides a method fortreating diabetes mellitus in a subject, comprising administering orallyto the subject a pharmaceutical composition comprising an insulin and anomega-3 fatty acid, thereby treating diabetes mellitus.

In one embodiment, the diabetes mellitus is Type I diabetes. In anotherembodiment, the diabetes mellitus is Type II diabetes. In anotherembodiment, the diabetes mellitus is insulin-dependent diabetes. Inanother embodiment, the diabetes mellitus is non-insulin-dependentdiabetes. In another embodiment, the diabetes mellitus is any other typeof diabetes known in the art. Each possibility represents a separateembodiment of the present invention.

In one embodiment, three treatments a day of the insulin composition areadministered. In another embodiment, two treatments a day areadministered. In another embodiment, four treatments a day areadministered. In another embodiment, one treatment a day isadministered. In another embodiment, more than four treatments a day areadministered. Each possibility represents a separate embodiment of thepresent invention.

Any of the methods of the present invention may utilize, in variousembodiments, any of the compositions of the present invention.

In another embodiment, the present invention provides a composition fororal administration of insulin, comprising an insulin protein and anomega-3 fatty acid, whereby a substantial fraction of the insulinretains the enzymatic activity after absorption through an intestinalmucosal barrier of the subject

In one embodiment, the present invention provides a composition for oraladministration of a protein, comprising a protein and an omega-3 fattyacid, whereby a substantial fraction of the protein retains theenzymatic activity after absorption through an intestinal mucosalbarrier of the subject.

In one embodiment, the present invention provides the use of a proteinand an omega-3 fatty acid in the manufacture of a medicament for oraladministration of a protein with an enzymatic activity to a subject,whereby a substantial fraction of the protein retains the enzymaticactivity after absorption through an intestinal mucosal barrier of thesubject.

In one embodiment, the present invention provides the use of an insulinprotein and an omega-3 fatty acid in the manufacture of a medicament fortreating diabetes mellitus in a subject.

In one embodiment, methods and compositions of the present inventionhave the advantage of more closely mimicking physiological insulinsecretion by the pancreas. When insulin is secreted into the portalvein, the liver is exposed to a greater insulin concentration thanperipheral tissues. Similarly, insulin administered according to thepresent invention reaches the intestine and is absorbed in the bodythrough the intestine and through the portal system to the liver. Thisabsorption route thus resembles the physiological secretion of insulinby the pancreas, enabling, in this embodiment, delicate control of theblood glucose level and the metabolic activities of the liver and theperipheral organs controlled by insulin. By contrast, when insulin isadministered to insulin-deficient diabetic patients via the peripheralvenous system, the concentration of insulin in the portal vein issimilar to that in the peripheral circulation, resulting inhypoinsulinemia in the portal vein and the liver and hyperinsulinemia inthe peripheral venous system. This leads, in one embodiment, to anabnormal pattern of glucose disposal.

In another embodiment, different constituents of compositions of thepresent composition are absorbed at different rates from the intestinallumen into the blood stream. The absorption of the bile acid, in oneembodiment, is significantly faster than the absorption of insulin.

For this reason, in another embodiment, a drug regimen involvingingestion of a pair of pills at spaced intervals, e.g., a second pillcontaining a higher concentration of enhancer is taken at a definedinterval (e.g. 30 minutes) after the first pill. In another embodiment,certain of the constituents are microencapsulated to enhance theabsorption of the insulin into the system.

In one embodiment, a treatment protocol of the present invention istherapeutic. In another embodiment, the protocol is prophylactic. Eachpossibility represents a separate embodiment of the present invention.

In another embodiment, solid carriers/diluents for use in methods andcompositions of the present invention include, but are not limited to, agum, a starch (e.g. corn starch, pregeletanized starch), a sugar (e.g.,lactose, mannitol, sucrose, dextrose), a cellulosic material (e.g.microcrystalline cellulose), an acrylate (e.g. polymethylacrylate),calcium carbonate, magnesium oxide, talc, or mixtures thereof.

In another embodiment, the compositions further comprise binders (e.g.acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum,hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone),disintegrating agents (e.g. cornstarch, potato starch, alginic acid,silicon dioxide, croscarmelose sodium, crospovidone, guar gum, sodiumstarch glycolate), buffers (e.g., Tris-HCI., acetate, phosphate) ofvarious pH and ionic strength, additives such as albumin or gelatin toprevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80,Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g.sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g.,glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid,sodium metabisulfite, butylated hydroxyanisole), stabilizers (e.g.hydroxypropyl cellulose, hyroxypropylmethyl cellulose), viscosityincreasing agents (e.g. carbomer, colloidal silicon dioxide, ethylcellulose, guar gum), sweeteners (e.g. aspartame, citric acid),preservatives (e.g., Thimerosal, benzyl alcohol, parabens), lubricants(e.g. stearic acid, magnesium stearate, polyethylene glycol, sodiumlauryl sulfate), flow-aids (e.g. colloidal silicon dioxide),plasticizers (e.g. diethyl phthalate, triethyl citrate), emulsifiers(e.g. carbomer, hydroxypropyl cellulose, sodium lauryl sulfate), polymercoatings (e.g., poloxamers or poloxamines), coating and film formingagents (e.g. ethyl cellulose, acrylates, polymethacrylates) and/oradjuvants. Each of the above excipients represents a separate embodimentof the present invention.

In some embodiments, the dosage forms of the present invention areformulated to achieve an immediate release profile, an extended releaseprofile, or a delayed release profile. In some embodiments, the releaseprofile of the composition is determined by using specific excipientsthat serve for example as binders, disintegrants, fillers, or coatingmaterials. In one embodiment, the composition will be formulated toachieve a particular release profile as known to one skilled in the art.

In one embodiment, the composition is formulated as an oral dosage form.In one embodiment, the composition is a solid oral dosage formcomprising tablets, chewable tablets, or capsules. In one embodiment thecapsules are soft gelatin capsules.

In other embodiments, controlled- or sustained-release coatings utilizedin methods and compositions of the present invention include formulationin lipophilic depots (e.g. fatty acids, waxes, oils).

The compositions also include, in another embodiment, incorporation ofthe active material into or onto particulate preparations of polymericcompounds such as polylactic acid, polglycolic acid, hydrogels, etc, oronto liposomes, microemulsions, micelles, unilamellar or multilamellarvesicles, erythrocyte ghosts, or spheroplasts.) Such compositions willinfluence the physical state, solubility, stability, rate of in vivorelease, and rate of in vivo clearance. In another embodiment,particulate compositions of the active ingredients are coated withpolymers (e.g. poloxamers or poloxamines)

In another embodiment, the compositions containing the insulin andomega-3 fatty acid are delivered in a vesicle, e.g. a liposome (seeLanger, Science 249:1527-1533 (1990); Treat et al., in Liposomes in theTherapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler(eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp.317-327; see generally ibid).

The preparation of pharmaceutical compositions that contain an activecomponent, for example by mixing, granulating, or tablet-formingprocesses, is well understood in the art. The active therapeuticingredient is often mixed with excipients that are pharmaceuticallyacceptable and compatible with the active ingredient. For oraladministration, the active ingredients of compositions of the presentinvention are mixed with additives customary for this purpose, such asvehicles, stabilizers, or inert diluents, and converted by customarymethods into suitable forms for administration, such as tablets, coatedtablets, hard or soft gelatin capsules, aqueous, alcoholic or oilysolutions.

Each of the above additives, excipients, formulations and methods ofadministration represents a separate embodiment of the presentinvention.

In one embodiment, the term “treating” refers to curing a disease. Inanother embodiment, “treating” refers to preventing a disease. Inanother embodiment, “treating” refers to reducing the incidence of adisease. In another embodiment, “treating” refers to amelioratingsymptoms of a disease. In another embodiment, “treating” refers toinducing remission. In another embodiment, “treating” refers to slowingthe progression of a disease.

EXPERIMENTAL DETAILS SECTION Example 1 Protection of Insulin fromProteases and Successful Administration Via the Duodenum in DogsMaterials and Experimental Methods Formulation

The day of dosing, a formulation containing 100 milligram (mg) EDTA(Sigma-Aldrich, St. Louis, Mo.), 100 mg soybean trypsin inhibitor (SBTI;Sigma), 5 mg insulin (recombinant crystalline) dissolved in 2 milliliter(ml) fish oil was prepared and inserted into a transparent gelatincapsule.

Results

To test whether insulin can be protected from proteases and absorbed viathe duodenum, a composition containing insulin, SBTI, EDTA, and fish oilwas administered directly to the duodenum of an 8.8 kg beagle dog. Bloodglucose was measured every 10 minutes following administration. Asdepicted below in Table 1, blood glucose levels were significantlyreduced in response to the insulin.

Thus, compositions comprising an omega-3 fatty acid can protect insulinfrom proteases in the small intestine and enable direct absorption oforally administered insulin.

TABLE 1 Blood glucose concentrations following administration of insulinto the duodenum in experiment #1. Time (min) Glucose inmilligrams/deciliter (mg/dL) −5 67 0 71 10 77 20 62 30 42 40 26 50 41 6036 75 35 90 51 105 64 120 75

Example 2 Materials and Experimental Methods Formulation

4 days prior to dosing, a formulation was prepared containing 125 mgEDTA, 100 mg SBTI, and 5 mg insulin in 2 ml fish oil in a gelatincapsule. The formulation was stored in the refrigerator (4° C.) untildosing.

Results

In the next experiment, a formulation of SBTI, EDTA, and fish oil wasprepared 4 days prior to dosing, then administered directly to theduodenum of a 9.0 kg beagle dog. As depicted below in Table 2, bloodglucose levels were significantly reduced in response to the insulin.

These results confirm the results of Example 1, showing thatcompositions comprising an omega-3 fatty acid can protect insulin fromproteases in the small intestine and enable direct absorption of orallyadministered insulin. In addition, these results show that compositionsof the present invention can be stored after constitution without losingpotency.

TABLE 2 Blood glucose concentrations following administration of insulinto the duodenum in experiment #2. Time (min) Glucose inmilligrams/deciliter (mg/dL) −5 69 0 68 10 64 20 38 30 19 40 31 50 39 6055 75 66 90 75 105 75 120 73

Example 3 Oral Administration of Pills Containing Insulin and Omega-3Fatty Acids Preparation of Tablet Cores

Tablet cores comprising insulin and omega-3 fatty acids are preparedusing methods well known in the art. For example, tablet cores may beprepared as described in Example 1.

Coating

The coating may be any delayed release coating known in the art. Forexample, the coating may be a polymer composed of the followingingredients:

4 mg Eudragit L-100 (Polymer of Acrylic and Methacrylic Acid Esters)

4 mg Talc NF

0.4 mg Polyethylene Glycol 6000 NF

In one embodiment, a solution of the enteric coated polymer is preparedby dissolving the polymer in a methylene chloride+isopropyl alcoholmixture. The tablets are coated by spraying the solution within a mildlywarmed jar under constant agitation. The solvent vapors are continuouslyaspirated.

Measurement of Levels and Activity of Recombinant Insulin in Subjects'Plasma

A human insulin radio-immunoassay (RIA) kit (Linco Research Inc, St.Charles, Mo.) is used to measure levels of recombinant insulin. Levelsof C peptide are measured as well, to determine the relativecontributions of endogenous and exogenous insulin to observed rises ininsulin levels.

Results

A mixture of EDTA, SBTI, and insulin dissolved in fish oil is formulatedinto tablet or capsule cores, coated with an enteric coating or gelatincoating, and administered to human subjects. Blood glucose levels of thesubjects are measured periodically as described in the previousExamples. In addition, the subjects' plasma levels of recombinantinsulin and its activity are tested. The coated pills are shown todeliver functional insulin to the subjects, and the insulinsignificantly lowers their blood glucose levels, showing that activeinsulin can be delivered to the bloodstream via oral administration.Different types of commercially available delayed release coatings aretested to determine which coating provides the best delivery of insulin,and this coating is used in subsequent Examples.

Example 4 Optimization of Source of Omega-3 Fatty Acids

Various omega-3 fatty acids or sources of omega-3 fatty acids (e.g.those listed above in the specification) are compared for their abilityto preserve insulin following oral administration in methods andcompositions of the present invention. Insulin tablets or capsules areformulated as described in the above Examples, except that the insulinis dissolved in the alternate source instead of in fish oil. The mosteffective source of omega-3 fatty acids is used in subsequent Examples.

Example 5 Optimization of Protease Inhibitors

Various protease inhibitors (either non-toxic or having an acceptabletoxicity profile; e.g. those listed above in the specification) arecompared for their ability to preserve insulin following oraladministration in methods and compositions of the present invention.Insulin tablets or capsules are formulated as described in the aboveExamples, except that the alternate protease inhibitors are substitutedfor SBTI. Amounts of the protease inhibitors are also varied, todetermine the optimal amounts. The most effective proteaseinhibitor/amount is used in subsequent Examples.

Example 6 Optimization of Enhancer

Various enhancers (e.g. those listed above in the specification) arecompared for their ability to facilitate absorption of insulin followingoral administration in methods and compositions of the presentinvention. Insulin tablets or capsules are formulated as described inthe above Examples, except that the alternate enhancers are substitutedfor EDTA. Amounts of the enhancers are also varied, to determine theoptimal amounts. The most effective enhancer/amount is used insubsequent experiments.

Example 7 Optimization of Type and Amount of Insulin

Various types and amounts of insulin e.g. those listed above in thespecification) are compared for their ability to regulate blood sugar inmethods and compositions of the present invention. Insulin tablets orcapsules are formulated as described in the above Examples, except thatthe type and amount of insulin is varied. The most effective type/amountof insulin is used in clinical trials.

1. A composition comprising a protein having a molecular weight of up to100,000 Daltons and an omega-3 fatty acid.
 2. The composition of claim1, wherein (a) said protein is insulin; (b) said omega-3 fatty acid isderived from fish oil; or (c) said inhibitor is soybean trypsininhibitor (SBTI).
 3. (canceled)
 4. The composition of claim 1, furthercomprising an inhibitor of a protease.
 5. (canceled)
 6. The compositionof claim 4, wherein (a) said inhibitor is AEBSF-HCI;(epsilon)-aminocaproic acid; (alpha)1-antichymotypsin; antipain;antithrombin III; (alpha)1-antitrypsin ([alpha]1-proteinase inhibitor);APMSF-HCI (4-amidinophenyl-methane sulfonyl-fluoride); sprotinin;benzamidine-HCI; chymostatin; DFP (diisopropylfluoro-phosphate);leupeptin; PEFABLOC® SC (4-(2-Aminoethyl)-benzenesulfonyl fluoridehydrochloride); PMSF (phenylmethyl sulfonyl fluoride); TLCK(1-Chloro-3-tosylamido-7-amino-2-beptanone HCI); TPCK(1-Chloro-3-tosylarnido-4-phenyl-2-butanone); trypsin inhibitor from eggwhite (Ovomucoid); trypsin inhibitor from soybean; aprotinin;pentamidine isethionate; pepstatin; guanidium; alpha2-macroglobulin; achelating agent of zinc; iodoacetate; or zinc; (b) said protease is aserine protease; or (c) said protease is trypsin. 7-8. (canceled)
 9. Thecomposition of claim 1, further comprising a substance that enhancesabsorption of said insulin protein through an intestinal mucosalbarrier.
 10. The composition of claim 9, wherein said substance is EDTA11. The composition of claim 9, wherein said substance is a bile acid oralkali metal salt thereof.
 12. The composition of claim 11, wherein saidbile acid is cholic acid, chenodeoxycholic acid, taurocholic acid,taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid,3.beta.-monohydroxychloric acid, lithocholic acid,3.alpha.-hydroxy-12-ketocholic acid, 3.beta.-hydroxy-12-ketocholic acid,12.alpha.-3.beta.-dihydrocholic acid, or ursodesoxycholic acid.
 13. Thecomposition of claim 1, further comprising a coating that inhibitsdigestion of said composition in a stomach of a subject.
 14. Thecomposition of claim 13, wherein said coating is an enteric coating orgelatin coating.
 15. A method for oral administration of a proteinhaving a molecular weight up to 100,000 Daltons to a subject, whereby asubstantial fraction of said protein retains its activity afterabsorption, through an intestinal mucosal barrier of said subject,comprising administering orally to said subject a pharmaceuticalcomposition comprising said protein and an omega-3 fatty acid.
 16. Themethod of claim 15, wherein (a) said protein is an enzyme; (b) saidprotein is insulin; (c) said protein is a glucagon, an interferon gamma,an interferon alpha, a growth hormone, an erythropoietin, or granulocytecolony stimulating factor (G-CSF); (d) said protein has a molecularweight of 1-50 kilodalton; (e) said protein is a receptor ligand,transport protein, storage protein or a combination thereof; or (f) saidcomposition further comprises omega-3 fatty acid derived from fish oil.17-21. (canceled)
 22. The method of claim 15, wherein saidpharmaceutical composition further comprises a protease inhibitor. 23.The method of claim 22, wherein (a) said inhibitor is soybean trypsininhibitor (SBTI); (b) said inhibitor is AEBSF-HCI;(epsilon)-aminocaproic acid; (alpha)1-antichymotypsin; antipain;antithrombin III; (alpha)1-antitrypsin ([alpha]1-proteinase inhibitor);APMSF-HCI (4-amidinophenyl-methane sulfonyl-fluoride); sprotinin;benzamidine-HCI; chymostatin; DFP (diisopropylfluoro-phosphate);leupeptin; PEFABLOC® SC (4-(2-Aminoethyl)-benzenesulfonyl fluoridehydrochloride); PMSF (phenylmethyl sulfonyl fluoride); TLCK(1-Chloro-3-tosylamido-7-amino-2-heptanone HCI); TPCK(1-Chloro-3-tosylamido-4-phenyl-2-butanone); trypsin inhibitor from eggwhite (Ovomucoid); trypsin inhibitor from soybean; aprotinin;pentamidine isethionate; pepstatin; guanidium; alpha2-macroglobulin; achelating agent of zinc; iodoacetate; or zinc; (c) wherein said proteaseis a serine protease; or (d) wherein said protease is trypsin. 24-26.(canceled)
 27. The method of claim 5, wherein said pharmaceuticalcomposition further comprises a substance that enhances absorption ofsaid protein through an intestinal mucosal barrier.
 28. The method ofclaim 27, wherein said substance is EDTA.
 29. The method of claim 27,wherein said substance is a bile acid or alkali metal salt thereof. 30.The method of claim 29, wherein said bile acid is cholic acid,chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid,glycocholic acid, glycochenocholic acid, 3.beta.-monohydroxychloricacid, lithocholic acid, 3.alpha.-hydroxy-12-ketocholic acid,3.beta.-hydroxy-12-ketocholic acid, 12.alpha.-3.beta.-dihydrocholicacid, or ursodesoxycholic acid.
 31. The method of claim 15, wherein saidpharmaceutical composition further comprises a coating that inhibitsdigestion of said composition in a stomach of a subject.
 32. The methodof claim 31, wherein said coating is an enteric coating or gelatincoating.
 33. A method for treating diabetes mellitus in a subject,comprising administering orally to said subject a pharmaceuticalcomposition comprising insulin and an omega-3 fatty acid, therebytreating diabetes mellitus.
 34. The method of claim 33, wherein (a) saidcomposition further comprises omega-3 fatty acid derived from fish oil;or (b) said pharmaceutical composition further comprises a coating thatinhibits digestion of said composition in a stomach of a subject. 35.The method of claim 33, wherein said pharmaceutical composition furthercomprises an inhibitor of a protease.
 36. The method of claim 35,wherein (a) said inhibitor is soybean trypsin inhibitor (SBTI); (b) saidinhibitor is AEBSF-HCI; (epsilon)-aminocaproic acid;(alpha)1-antichymotypsin; antipain; antithrombin III;(alpha)1-antitrypsin ([alpha]1-proteinase inhibitor); APMSF-HCI(4-ainidinophenyl-methane sulfonyl-fluoride); sprotinin;benzamidine-HCI; chymostatin; DFP (diisopropylfluoro-phosphate);leupeptin; PEFABLOC® SC (4-(2 Aminoethyl)-benzenesulfonyl fluoridehydrochloride); PMSF (phenylmethyl sulfonyl fluoride); TLCK(1-Chloro-3-tosylamido-7-amino-2-heptanone HCI); TPCK(1-Chloro-3-tosylamido-4-phenyl-2-butanone); trypsin inhibitor from eggwhite (Ovomucoid); trypsin inhibitor from soybean; aprotinin;pentamidine isethionate; pepstatin; guanidium; alpha2-macroglobulin; achelating agent of zinc; iodoacetate; or zinc; (c) said protease is aserine protease; or (d) said protease is trypsin. 37-39. (canceled) 40.The method of claim 33, wherein said pharmaceutical composition furthercomprises a substance that enhances absorption of said insulin proteinthrough an intestinal mucosal barrier.
 41. The method of claim 40,wherein said substance is EDTA.
 42. The method of claim 40, wherein saidsubstance is a bile acid or alkali metal salt thereof.
 43. The method ofclaim 42, wherein said bile acid is cholic acid, chenodeoxycholic acid,taurncholic acid, taurochenodeoxycholic acid, glycocholic acid,glycochenocholic acid, 3.beta.-monohydroxychloric acid, lithocholicacid, 3.alpha.-hydroxy-12-ketocholic acid, 3.beta.-hydroxy-12-ketocholicacid, 12.alpha.-3.beta.-dihydrocholic acid, or ursodesoxycholic acid.44. (canceled)
 45. The method of claim 41, wherein said coating is anenteric coating or gelatin coating.